drugset
drugset / Trial / NCT02413580

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

NCT02413580 ↗

Phase 3 Completed 49 enrolled Grifols Therapeutics LLC
NaSingle-groupOpen-labelTreatment

Summary

This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.

Timeline

Start
2015-03
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 2 g/kg Intravenous

Indications

myasthenia gravis